At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
The Clareon™ PanOptix™ Trifocal (toric and non-toric models)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
In Brief
An observational study evaluating The Clareon™ PanOptix™ Trifocal (toric and non-toric models) for Cataract. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To evaluate visual outcomes and quality of vision following bilateral implantation of the Clareon PanOptix intraocular lens (IOL) targeted for emmetropia.
Study Details
Timeline
N/ACompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartSep 2022
Primary CompletionJun 2024
TodayJul 2026
First PostedAug 26, 2022
Enrollment StartSep 8, 2022
Primary CompletionJun 14, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.9 years ago
Interventions
The Clareon™ PanOptix™ Trifocal (toric and non-toric models)device
Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)